Pharmacokinetic of Sevoflurane During a 48h Sedation in Intensive Care Unit With AnaConDa®

N/ACompletedNCT01196754

University Hospital, Clermont-Ferrand12 enrolled

Overview

This is a prospective clinical monocentric study in ICU with sedated ventilated patients with sevoflurane during 48 h with the AnaConda® system, establishing pharmacokinetic model of sevoflurane.

Prospective clinical monocentric study in ICU with sedated ventilated patients with sevoflurane during 48 h with the AnaConda® system, establishing pharmacokinetic model of sévoflurane and its metabolites (hydroxyfluroisopropanol, fluoride)

Study Type

INTERVENTIONAL

Purpose

SCREENING

Enrollment

Conditions

Sedation

Interventions

sevofluraneOTHER

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients ventilated more than 48 h * Stable respiratory and hemodynamic conditions * Consent of patients or family * Arterial line Exclusion Criteria: * Acute kidney injury * Obesity * Sevoflurane anaphylaxia

Locations (1)

CHU Clermont-Ferrand

Clermont-Ferrand, France

Outcomes

Primary Outcomes

Determination of plasmatic concentrations of sévoflurane at different times of a 48h sedation of sévoflurane.

Time frame: during 48 hours

Secondary Outcomes

Determination of plasmatic concentrations of HFIP and fluoride at different times of a 48h sedation of sévoflurane. Determination of a pharmacokinetic model of sévoflurane.

Time frame: during 48 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.